Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1977 1
1978 7
1979 6
1980 146
1981 342
1982 433
1983 343
1984 433
1985 450
1986 479
1987 614
1988 691
1989 725
1990 784
1991 840
1992 887
1993 993
1994 1051
1995 1051
1996 1192
1997 1267
1998 1311
1999 1293
2000 1370
2001 1445
2002 1545
2003 1739
2004 1886
2005 2248
2006 2498
2007 2683
2008 3165
2009 3461
2010 3917
2011 4304
2012 4514
2013 4802
2014 4809
2015 4723
2016 4672
2017 4577
2018 4689
2019 4538
2020 3330
2021 6
Text availability
Article attribute
Article type
Publication date

Search Results

77,422 results
Results by year
Filters applied: . Clear all The following term was not found in PubMed: 029656
Page 1
ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.
Cramer PE, Cirrito JR, Wesson DW, Lee CY, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE. Cramer PE, et al. Science. 2012 Mar 23;335(6075):1503-6. doi: 10.1126/science.1217697. Epub 2012 Feb 9. Science. 2012. PMID: 22323736 Free PMC article.
Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.
Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Dave CV, et al. Ann Intern Med. 2019 Aug 20;171(4):248-256. doi: 10.7326/M18-3136. Epub 2019 Jul 30. Ann Intern Med. 2019. PMID: 31357213 Free PMC article.
OBJECTIVE: To assess whether patients initiating use of SGLT-2 inhibitors were at increased risk for severe UTI events compared with those initiating use of dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like peptide-1 receptor (GLP-1) agonists. ...Patients were age …
OBJECTIVE: To assess whether patients initiating use of SGLT-2 inhibitors were at increased risk for severe UTI events compared with those i …
Small-molecule TFEB pathway agonists that ameliorate metabolic syndrome in mice and extend C. elegans lifespan.
Wang C, Niederstrasser H, Douglas PM, Lin R, Jaramillo J, Li Y, Oswald NW, Zhou A, McMillan EA, Mendiratta S, Wang Z, Zhao T, Lin Z, Luo M, Huang G, Brekken RA, Posner BA, MacMillan JB, Gao J, White MA. Wang C, et al. Nat Commun. 2017 Dec 22;8(1):2270. doi: 10.1038/s41467-017-02332-3. Nat Commun. 2017. PMID: 29273768 Free PMC article.
Here, we report a nanotechnology-enabled high-throughput screen to identify small-molecule agonists of TFEB and discover three novel compounds that promote autophagolysosomal activity. ...
Here, we report a nanotechnology-enabled high-throughput screen to identify small-molecule agonists of TFEB and discover three novel …
Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study.
Fralick M, Kim SC, Schneeweiss S, Kim D, Redelmeier DA, Patorno E. Fralick M, et al. Ann Intern Med. 2019 Feb 5;170(3):155-163. doi: 10.7326/M18-0567. Epub 2019 Jan 1. Ann Intern Med. 2019. PMID: 30597484 Free PMC article.
The rate of the primary outcome was similar for canagliflozin (2.2 events per 1000 person-years) and GLP-1 agonists (2.3 events per 1000 person-years), with an overall HR of 0.98 (95% CI, 0.75 to 1.26). ...CONCLUSION: In this study of middle-aged patients with type 2 diabe …
The rate of the primary outcome was similar for canagliflozin (2.2 events per 1000 person-years) and GLP-1 agonists (2.3 events per 1 …
Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.
Patorno E, Goldfine AB, Schneeweiss S, Everett BM, Glynn RJ, Liu J, Kim SC. Patorno E, et al. BMJ. 2018 Feb 6;360:k119. doi: 10.1136/bmj.k119. BMJ. 2018. PMID: 29437648 Free PMC article.
OBJECTIVE: To evaluate the cardiovascular safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus, in direct comparisons with DPP-4 inhibitors (DPP-4i), GLP-1 receptor agonists (GLP-1RA), or sulfonylureas, as used i …
OBJECTIVE: To evaluate the cardiovascular safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor for the treatment of type 2 di …
An overview of the cannabinoid type 2 receptor system and its therapeutic potential.
Bie B, Wu J, Foss JF, Naguib M. Bie B, et al. Curr Opin Anaesthesiol. 2018 Aug;31(4):407-414. doi: 10.1097/ACO.0000000000000616. Curr Opin Anaesthesiol. 2018. PMID: 29794855 Free PMC article. Review.
Treatment for mild cognitive impairment: systematic review.
Cooper C, Li R, Lyketsos C, Livingston G. Cooper C, et al. Br J Psychiatry. 2013 Sep;203(3):255-64. doi: 10.1192/bjp.bp.113.127811. Br J Psychiatry. 2013. PMID: 24085737 Free PMC article. Review.
Extragonadal Actions of FSH: A Critical Need for Novel Genetic Models.
Kumar TR. Kumar TR. Endocrinology. 2018 Jan 1;159(1):2-8. doi: 10.1210/en.2017-03118. Endocrinology. 2018. PMID: 29236987 Free PMC article. Review.
Ingestion of transient receptor potential channel agonists attenuates exercise-induced muscle cramps.
Craighead DH, Shank SW, Gottschall JS, Passe DH, Murray B, Alexander LM, Kenney WL. Craighead DH, et al. Muscle Nerve. 2017 Sep;56(3):379-385. doi: 10.1002/mus.25611. Epub 2017 May 9. Muscle Nerve. 2017. PMID: 28192854 Free PMC article. Clinical Trial.
Ingestion of transient receptor potential (TRP) channel agonists has been efficacious in attenuating electrically induced muscle cramps. ...
Ingestion of transient receptor potential (TRP) channel agonists has been efficacious in attenuating electrically induced muscle cram …
Gonadotropin-releasing hormone agonist in premenopausal women does not alter hypothalamic-pituitary-adrenal axis response to corticotropin-releasing hormone.
Gavin KM, Shea KL, Gibbons E, Wolfe P, Schwartz RS, Wierman ME, Kohrt WM. Gavin KM, et al. Am J Physiol Endocrinol Metab. 2018 Aug 1;315(2):E316-E325. doi: 10.1152/ajpendo.00221.2017. Epub 2018 Apr 6. Am J Physiol Endocrinol Metab. 2018. PMID: 29631362 Free PMC article. Clinical Trial.
Thirty premenopausal women underwent 20 wk of gonadotropin-releasing hormone agonist therapy (GnRH(AG)) and transdermal E(2) (0.075 mg per day, GnRH(AG)+ E(2), n= 15) or placebo (PL) patch (GnRH(AG)+ PL, n= 15). Women in the GnRH(AG)+ PL and GnRH(AG
Thirty premenopausal women underwent 20 wk of gonadotropin-releasing hormone agonist therapy (GnRH(AG)) and transdermal E(2) (0.075 m …
77,422 results
Jump to page
Feedback